Aspirin effect on blood clotting in kidney disease
Treatments studied
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study checks how aspirin (also called salicylate) affects how platelets work, which helps blood clot. It involves people with advanced chronic kidney disease who are treated with Aranesp, and it may help guide safer care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic kidney disease and are on dialysis (hemodialysis or peritoneal dialysis) or CKD stage 5 treated without dialysis
- You are between 18 and 85 years old
- You are currently supposed to receive Aranesp or another ESA for anemia
- You are able to give informed consent and can follow study instructions
- Your iron levels are not in the “iron deficiency” range (or have been corrected before the study)
- Your Aranesp (darbepoetin alfa) dose has been stable (about 20 micrograms per week or less change, and no large dose change in the last 2 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking aspirin can reduce heart and clot-related complications in adults receiving long-term dialysis. It may help by improving blood clotting behavior, but it also requires that aspirin is safe for you.
This study looks at whether taking a daily aspirin medicine during and after extracorporeal shockwave treatment for a kidney stone helps keep the blood from “clumping” too much. It will compare different maintenance approaches while monitoring safety, especially bleeding risk.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This study tests whether a low dose of aspirin can protect the kidneys in people with early diabetic kidney disease. It aims to see if aspirin slows down kidney damage without causing serious side effects.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
Hear when a new Erythropoietin Adverse Reaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.